《異動股》恆發光學(01134.HK)續漲21%屢破頂 最近15個交易日累飆2倍
恆發光學(01134.HK)由11月13日收市價0.57元開始發力,15個交易日僅1天平收餘下均升,本周二股價更突破首掛日盤中所造高位1.32元,今天高見1.72元,現造1.67元,續漲21%,較上月13日收市價更累飆1.9倍;一向薄弱成交倍增至431萬股。
恆發光學是一間著名中港眼鏡製造商,主要通過ODM及OEM業務模式生產及銷售多種光學眼鏡架及太陽眼鏡。股份於去年7月中旬以每股1元上市,淨籌8,070萬元,主要用作提高產能、還債、提升設計與開發能力及推廣等。上市獨家保薦人信達國際。
受累於新冠肺炎大疫情大流行,該公司今年上半年業績扭盈轉蝕825.7萬元。此外,公司上月公布,為減輕疫情的不利影響及維持穩健財務狀況,集團決定暫時擱置擴大集團於江西產能及減少推廣等,將上市集資所得未動用款項2,000萬元重新分配為集團一般營運資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.